Allspring Global Investments
VIRX

Allspring Global Investments’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Allspring Global Investments’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-87,795
Closed -$417K – 2978
2022
Q1 		$417K Buy
87,795
+14,784
+20% +$44.5K ﹤0.01% 2298
2021
Q4 		$266K Buy
+73,011
New +$390K ﹤0.01% 2551

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Allspring Global Investments's VIRX Position: Q2 2022 in Review

Allspring Global Investments sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2022, closing a stake of 87,795 shares — an estimated $417K sold.

Allspring Global Investments first reported a position in VIRX in Q4 2021 and held it in 2 quarters. The position peaked at $417K in Q1 2022. 63 funds tracked by Wall St. Rank hold VIRX as of Q2 2022.

  • Allspring Global Investments reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Allspring Global Investments sold 87,795 Viracta Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $417K.
  • Allspring Global Investments first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • Allspring Global Investments's Viracta Therapeutics, Inc. Common Stock position peaked at $417K in Q1 2022.
  • 63 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Allspring Global Investments's 13F filing for Q2 2022, filed 25 Jul 2022.